Tuesday, January 19, 2016

What is Ophelia's interaction with Polonius in Act 1, Scene 3 of Hamlet?

Polonius advises Ophelia against a relationship with Hamlet.


Laertes, Ophelia’s brother, counsels her to avoid Hamlet’s advances. He tells her that royalty is fickle and she will just get hurt.  He is her brother, and he is looking out for her.  Then her father enters, and asks what Laertes advised.


Ophelia tells him they were talking about Hamlet, and Polonius adds his caution to Laertes’s.  He tells Ophelia that he is aware that she has been thinking about Hamlet, and that she should be careful.  Like Laertes, he does not believe that Hamlet’s intentions are pure.



OPHELIA


He hath, my lord, of late made many tenders
Of his affection to me.


LORD POLONIUS


Affection! pooh! you speak like a green girl,
Unsifted in such perilous circumstance.
Do you believe his tenders, as you call them? (Act 1, Scene 3)



Poor Ophelia is getting it from all sides!  She is a sensitive girl, and she does not want to question Hamlet’s integrity.  However, her brother and father see her as a vulnerable damsel and feel the need to intervene before Hamlet takes her honor. Ophelia assures him that Hamlet’s intentions are good, but he tells her it is all an act.



For Lord Hamlet,
Believe so much in him, that he is young
And with a larger tether may he walk
Than may be given you: in few, Ophelia,
Do not believe his vows; for they are brokers,
Not of that dye which their investments show,
But mere implorators of unholy suits,
Breathing like sanctified and pious bawds,
The better to beguile. (Act 1, Scene 3)



In a way, the two men are right.  Hamlet is not to be trusted.  He may have feelings for Ophelia, but he manipulates her and uses her very badly.  He must see how fragile she is, but he continues to mess with her head.  He has bigger problems than her.  He wants to make everyone believe he is crazy because he needs to avenge his father, and she is just the tool to do it.

Throughout the course of The Crucible, does Danforth change?

At the risk of giving him too much credit, I do think Danforth changes.  When the audience first meets him in Act Three, he seems to honestly believe that the girls are telling the truth when they accuse others of witchcraft.  That the Puritan religion admitted both the existence of witches as well as the possibility of the devil working constantly in their daily lives to tempt and corrupt them meant that Danforth could legitimately believe the seemingly wild stories the girls were telling him.  He says, "We burn a hot fire [in this court]; it melts down all concealment," and I think he believes that this is true because of the evidence (convincing to him and others) he's heard from both the girls and the people who confessed to witchcraft.


By Act 4, however, Danforth has changed.  I think he now recognizes that the girls were lying.  He calls Reverend Parris "a brainless man" now that Abigail and Mercy Lewis have robbed him and run off, and certainly Abigail's theft and flight make her look immoral and guilty.  Further, he seems more concerned about his and the court's authority now than he does about truth.  When Parris and Hale ask him to postpone the hangings, he refuses, saying, "Postponement now speaks a floundering on my part; reprieve or pardon must cast doubt upon the guilt of them that died till now."  Even if all those who've been hanged were innocent, he cannot now seem to admit the possibility because it would mean that he and the other judges have been tricked.  He swears that, if the town should rebel, he would rather hang them all than appear weak.  Therefore, during the course of the play, Danforth seems to have lost sight of what is important: truth.  By the end, retaining his own reputation, authority, and appearance of righteousness trumps his concern for truth.

How would I write a character sketch of Helen Keller?

Helen Keller was born with all of her senses, but contracted an illness as a child that left her blind and deaf.  Despite her disabilities, Helen Keller learned to read and write, went to college, and became an advocate for the blind. 


When writing a character sketch, you want to give details about the person that are included in the story. These can include physical and personality traits. You can support these with examples from the text and quotations.


Helen is determined, intelligent, and sensitive. These traits initially made it difficult for her teacher, Anne Sullivan, to teach her language. When she began to learn, though, there was no stopping Helen. She learned quickly and came to love knowledge.


In The Story of My Life, Helen describes how she felt at the end of the first day in which she learned words:



I learned a great many new words that day… It would have been difficult to find a happier child than I was as I lay in my crib at the close of the eventful day and lived over the joys it had brought me, and for the first time longed for a new day to come (Chapter 4).



Helen had existed in a state of darkness and ignorance, unable to communicate with anyone. Once she learned her first word, “water,” she was able to learn many more. Anne Sullivan spelled into her hand. Helen came to associate this with the words. 


Even after this, Helen did not have an easy life. The world was still sometimes foreign and difficult for her to navigate. For example, she loved nature, but was frightened when she climbed a tree and a storm hit. Without being able to see or hear, Helen sometimes found the world confusing and scary.


Helen was successful enough that she even went to Radcliff College. College was not easy for Helen Keller, since few of her schoolbooks were in braille and everything took her longer. Still, Helen persevered and became a writer and a successful advocate for the blind.

Monday, January 18, 2016

How did the peace treaty ending World War I both follow and violate the principle of self-determination ?

One of the goals that Woodrow Wilson wanted to accomplish as the Allies prepared to develop a peace treaty ending World War I was to allow people in many countries to be ruled by their own people. In some ways, this was accomplished. Polish people ran the government of Poland. The southern and eastern Slavic groups controlled and ran the governments of Yugoslavia and Czechoslovakia. In these countries, the principle of self-determination was very evident.


However, self-determination didn’t exist everywhere. The splitting of the Ottoman Empire didn’t lead to people being ruled by their own people. After World War I ended, much of the Middle East was given to Great Britain and France. These countries ruled the Middle East for many years before some of these countries became independent.


Self-determination was one of our goals in World War I, but it didn’t occur everywhere after the war ended.

According to David, how did it happen that he and Rosalind fell in love in The Chrysalids?

David says that he has loved Rosalind as long as he can remember.


All of the telepaths are very close.  Being able to read another person’s mind is an intimate thing.  David and Rosalind grow to love each other while they are young, and as they get older they realize that they will marry one another someday. It just seems natural.



Quite when it was that we had known we were going to marry one another, neither of us has been able to remember. It was one of those things that seem ordained, in such proper accord with the law of nature and our own desires, that we felt we had always known it. (Ch. 10) 



When Anne falls in love with a man who is not a telepath, Allen, she tries to explain to the others that they will not understand because none of them have been in love except David and Rosalind.  The others tell her that she can’t marry a normal person, but as Uncle Axel tells David, you can’t question a woman in love.


David and Rosalind’s relationship is forbidden because of a feud between their parents.  It does not stop them.  Their love and their unusual abilities make them above such considerations.  Still, they have to meet in secret.



We used to meet, discreetly and not dangerously often. No one but the others, I think, ever suspected anything between us. We had to make love in a snatched, unhappy way when we did meet, wondering miserably whether there would ever be a time when we should not have to hide ourselves. (Ch. 10) 



Because of their secret, David wonders what would happen if Rosalind got pregnant.  His parents would not approve of the marriage, and his father is powerful.  Eventually, the telepaths will have to go on the run. 


Everything from Anne blows up, and their cover is blown.  Alan is killed and Anne thinks one of the telepaths did it and commits suicide.  Soon after, Petra panics when her horse is being attacked by a mutant and calls the others.  They have a hard time explaining how they knew to go there since she made no sound, and their secret is out.

What are death and dying?


Causes and Symptoms

Medicine determines that death has occurred by assessing bodily functions in either of two areas. Persons with irreversible cessation of respiration and circulation are dead; persons with irreversible cessation of ascertainable brain functions are also dead. There are standard procedures used to diagnose death, including simple observation, brain-stem reflex studies, and the use of confirmatory testing such as electrocardiography (ECG or EKG), electroencephalography (EEG), and arterial blood gas analysis (ABG). The particular circumstances—anticipated or unanticipated, observed or unobserved, the patient’s age, drug or metabolic intoxication, or suspicion of hypothermia—will favor some procedures over others, but in all cases both cessation of functions and their irreversibility are required before death can be declared.



About 65 percent of all Americans died from chronic conditions in 2013, according to the US Centers for Disease Control and Prevention. The Council for Foreign Relations also reported in 2014 that chronic conditions were responsible for the premature deaths (at age fifty-nine or younger) of 8 million people living in developing countries in the preceding year. Therefore, except in sudden death (as in a fatal accident) or when there is no evidence of consciousness (as in a head injury that destroys cerebral functions while leaving brain-stem reflexive functions intact), dying is both a physical and a psychological process. In most cases, dying takes time, and the time allows patients to react to the reality of their own passing. Often, they react by becoming vigilant about bodily symptoms and any changes in them. They also anticipate changes that have yet to occur. For example, long before the terminal stages of illness become manifest, dying patients commonly fear physical pain, shortness of breath, invasive procedures, loneliness, becoming a burden to loved ones, losing decision-making authority, and facing the unknown of death itself.


As physical deterioration proceeds, all people cope by resorting to what has worked for them before: the unique means and mechanisms that have helped maintain a sense of self and personal stability. People seem to go through the process of dying much as they have gone through the process of living—with the more salient features of their personalities, whether good or bad, becoming sharper and more prominent. People seem to face death much as they have faced life.


Medicine has come to acknowledge that physicians should understand what it means to die. Indeed, while all persons should understand what their own deaths will mean, physicians must additionally understand how their dying patients find this meaning.


In 1969, psychiatrist Elisabeth Kübler-Ross published the landmark On Death and Dying, based on her work with two hundred terminally ill patients. Though the work of Kübler-Ross has been criticized for the nature of the stages described and whether or not every person experiences every stage, her model has retained enormous utility to those who work in the area of death and dying. Technologically driven Western medicine had come to define its role as primarily dealing with extending life and thwarting death by defeating specific diseases. Too few physicians saw a role for themselves once the prognosis turned grave. In the decades that followed the publication of On Death and Dying, the profession has reaccepted that death and dying are part of life and that, while treating the dying may not mean extending the length of life, it can and should mean improving its quality.


Kübler-Ross provided a framework to explain how people cope with and adapt to the profound and terrible news that their illness is terminal. Although other physicians, psychologists, and thanatologists have shortened, expanded, and adapted her five stages of the dying process, neither the actual number of stages nor what they are specifically called is as important as the information and insight that any stage theory of dying yields. As with any human process, dying is complex, multifaceted, multidimensional, and polymorphic.


Well-intentioned, but misguided, professionals and family members may try to help move dying patients through each of the stages only to encounter active resentment or passive withdrawal. Patients, even dying patients, cannot be psychologically moved to where they are not ready to be. Rather than making the terminally ill die the “right” way, it is more respectful and helpful to understand any stage as a description of normal reactions to serious loss, and that these reactions normally vary among different individuals and also within the same individual over time. The reactions appear, disappear, and reappear in any order and in any combination. What the living must do is respect the unfolding of an adaptational schema that is the dying person’s own. No one should presume to know how someone else should prepare for death.




Complications and Disorders

Kübler-Ross defined five stages of grief. Denial is the first stage defined by Kübler-Ross, but it is also linked to shock and isolation. Whether the news is told outright or gradual self-realization occurs, most people react to the knowledge of their impending death with existential shock: Their whole selves recoil at the idea, and they say, in some fashion, “This cannot be happening to me.” Broadly considered, denial is a complex cognitive-emotional capacity that enables temporary postponement of active, acute, but in some way detrimental, recognition of reality. In the dying process, this putting off of the truth prevents a person from being overwhelmed while promoting psychological survival. Denial plays an important stabilizing role, holding back more than could be otherwise managed while allowing the individual to marshal psychological resources and reserves. It enables patients to consider the possibility, even the inevitability, of death and then to put the consideration away so that they can pursue life in the ways that are still available. In this way, denial is truly a mechanism of defense.


Many other researchers, along with Kübler-Ross, report anger as the second stage of dying. The stage is also linked to rage, fury, envy, resentment, and loathing. When “This cannot be happening to me” becomes, “This is happening to me. There was no mistake,” patients are beginning to replace denial with attempts to understand what is happening to and inside them. When they do, they often ask, “Why me?” Though it is an unanswerable question, the logic of the question is clear. People, to remain human, must try to make intelligible their experiences and reality. The asking of this question is an important feature of the way in which all dying persons adapt to and cope with the reality of death.


People react with anger when they lose something of value; they react with greater anger when something of value is taken away from them by someone or something. Rage and fury, in fact, are often more accurate descriptions of people’s reactions to the loss of their own life than is anger. Anger is a difficult stage for professionals and loved ones, more so when the anger and rage are displaced and projected randomly into any corner of the patient’s world. An unfortunate result is that caregivers often experience the anger as personal, and the caregivers’ own feelings of grief and guilt, shame, and rejection can contribute to lessening contact with the dying person, which increases his or her sense of isolation.


Bargaining is Kübler-Ross’s third stage, but it is also the one about which she wrote the least and the one that other thanatologists are most likely to leave unrepresented in their own models and stages of how people cope with dying. Nevertheless, it is a common phenomenon wherein dying people fall back on their faith, belief systems, or sense of the transcendent and the spiritual and try to make a deal—with god, life, fate, a higher power, or the universe. They ask for more time to help family members reconcile or to achieve something of importance. They may ask if they can simply attend their child’s wedding or graduation or if they can see their first grandchild born. Then they will be ready to die; they will go willingly. Often, they mean that they will die without fighting death, if death can only be delayed or will delay itself.


At some point, when terminally ill individuals are faced with decisions about more procedures, tests, surgeries, or medications or when their thinness, weakness, or deterioration becomes impossible to ignore, the anger, rage, numbness, stoicism, and even humor will likely give way to depression, Kübler-Ross’s fourth stage and the one reaction that all thanatologists include in their models of how people cope with dying.


The depression can take many forms, for indeed there are always many losses, and each loss individually or several losses collectively might need to be experienced and worked through. For example, dying parents might ask themselves who will take care of the children, get them through school, walk them down the aisle, or guide them through life. Children, even adult children who are parents themselves, may ask whether they can cope without their own parents. They wonder who will support and anchor them in times of distress, who will (or could) love, nurture, and nourish them the way that their parents did. Depression accompanies the realization that each role, each function, will never be performed again. Both the dying and those who love them mourn.


Much of the depression takes the form of anticipatory grieving, which often occurs both in the dying and in those who will be affected by their death. It is a part of the dying process experienced by the living, both terminal and nonterminal. Patients, family, and friends can psychologically anticipate what it will be like when the death does occur and what life will, and will not, be like afterward. The grieving begins while there is still life left to live.


Bereavement specialists generally agree that anticipatory grieving, when it occurs, seems to help people cope with what is a terrible and frightening loss. It is an adaptive psychological mechanism wherein emotional, mental, and existential stability are painfully maintained. When depression develops, not only in reaction to death but also in preparation for it, it seems to be a necessary part of how those who are left behind cope to survive the loss themselves. Those who advocate or advise cheering up or looking on the bright side are either unrealistic or unable to tolerate the sadness in themselves or others. The dying are in the process of losing everything and everyone they love. Cheering up does not help them; the advice to “be strong” only helps the “helpers” deny the truth of the dying experience.


Both preparatory and reactive depression are frequently accompanied by unrealistic self-recrimination, shame, and guilt in the dying person. Those who are dying may judge themselves harshly and criticize themselves for the wrongs that they committed and for the good that they did not accomplish. They may judge themselves to be unattractive, unappealing, and repulsive because of how the illness and its treatment have affected them. These feelings and states of minds, which have nothing to do with the reality of the situation, are often amenable to the interventions of understanding and caring people. Financial and other obligations can be restructured and reassigned. Being forgiven and forgiving can help finish what was left undone.


Kübler-Ross’s fifth stage, acceptance, is an intellectual and emotional coming to terms with death’s reality, permanence, and inevitability. Ironically, it is manifested by diminished emotionality and interests and increased fatigue and inner (many would say spiritual) self-focus. It is a time without depression or anger. Envy of the healthy, the fear of losing all, and bargaining for another day or week are also absent. This final stage is often misunderstood. Some see it either as resignation and giving up or as achieving a happy serenity. Some think that acceptance is the goal of dying well and that all people are supposed to go through this stage. None of these viewpoints is accurate. Acceptance, when it does occur, comes from within the dying person. It is marked more by an emotional void and psychological detachment from people and things once held important and necessary and by an interest in some transcendental value (for the atheist) or god (for the theist). It has little to do with what others believe is important or “should” be done. It is when dying people become more intimate with themselves and appreciate their separateness from others more than at any other time.




Perspective and Prospects

Every person will eventually die, and the fact of death in each life is one that varies by culture in terms of its meaning. For some cultures, dying is seen as the ultimate difficulty for dying people and their loved ones. For other cultures, it is seen as not difficult at all, but more so like passing on to another realm of existence. In Western cultures, however, dying has very much become a medical process, and it is often a process filled with challenging questions. Patients ask questions that cannot be answered; families in despair and anger seek to find cause and sometimes to lay blame. It takes courage to be with individuals as they face their deaths, struggling to find meaning in the time that they have left. Given this, in Western medicine, a profession that prides itself on how well it intervenes to avoid outcomes like death, it takes courage to witness the process and struggle involved in death. Working with death also reminds professionals of their own inevitable death. Facing that fact inwardly, spiritually, and existentially also requires courage.


Cure and treatment become care and management in the dying. They should live relatively pain-free, be supported in accomplishing their goals, be respected, be involved in decision making as appropriate, be encouraged to function as fully as their illness allows, and be provided with others to whom control can comfortably and confidently be passed. The lack of a cure and the certainty of the end can intimidate health care providers, family members, and close friends. They may dread genuine encounters with those whose days are knowingly numbered. Yet the dying have the same rights to be helped as any of the living, and how a society assists them bears directly on the meaning that its members are willing to attach to their own lives.


In the twenty-first century, largely in response to what dying patients have told researchers, medicine recognizes its role to assist these patients in working toward an appropriate death. Caretakers must determine the optimum treatments, interventions, and conditions that will enable such a death to occur. With the view of respecting individuals' dying wishes and of easing the burden of decision making for caretakers, much public attention has turned toward advance care planning for end of life, in which individuals communicate ahead of time which treatments and interventions they wish and do not wish to receive when experiencing a life-threatening event or illness. For each person, these plans should be unique and specific. Caretakers should respond to the patient’s needs and priorities, at the patient’s own pace and as much as possible following the patient’s lead. For some dying patients, the goal is to remain as pain-free as is feasible and to feel as well as possible. For others, finishing whatever unfinished business remains becomes the priority. Making amends, forgiving and being forgiven, resolving old conflicts, and reconciling with one's self and others may be the most therapeutic and healing of interventions. Those who are to be bereaved fear the death of those they love. The dying fear separation from all they know and love, but they fear as well the loss of autonomy, letting family and friends down, the pain and invasion of further treatment, disfigurement, dementia, loneliness, the unknown, becoming a burden, and loss of dignity. Many of those fears of have lent support for "death with dignity" laws, which allow terminally ill persons of sound mind to end their lives voluntarily with a prescription medication before their illnesses incapacitate them.


The English writer C. S. Lewis said that bereavement is the universal and integral part of the experience of loss. It requires effort, authenticity, mental and emotional work, a willingness to be afraid, and an openness to what is happening and what is going to happen. It requires an attitude that accepts, tolerates suffering, takes respite from the reality, reinvests in whatever life remains, and moves on. The only way to cope with dying or witnessing the dying of loved ones is by grieving through the pain, fear, loneliness, and loss of meaning. This process, which researcher Stephen Levine has likened to opening the heart in hell, is a viscous morass for most, and all people need to learn their own way through it and to have that learning respected. Healing begins with the first halting, unsteady, and frightening steps of genuine grief, which sometimes occur years before the “time of death” can be recorded.




Bibliography


"Advanced Illness: Holding On and Letting Go." Family Caregiver Alliance, 2013.



Becker, Ernest. The Denial of Death. New York: Free Press, 1997.



Callahan, Maggie, and Patricia Kelley. Final Gifts: Understanding the Special Awareness, Needs, and Communications of the Dying. New York: Simon & Schuster, 1992.



Clancy, Carolyn M. "Talking about End-of-Life Treatment Decisions." Agency for Healthcare Research and Quality, July 7, 2009.



Cook, Alicia Skinner, and Daniel S. Dworkin. Helping the Bereaved: Therapeutic Interventions for Children, Adolescents, and Adults. New York: Basic Books, 1992.



Corr, Charles A., and Donna M. Corr. Death and Dying, Life and Living. 7th ed. Belmont, Calif.: Wadsworth, 2012.



"End of Life: Helping with Comfort and Care." National Institute on Aging, June 26, 2013.



Forman, Walter B., et al., eds. Hospice and Palliative Care: Concepts and Practice. 2d ed. Sudbury, Mass.: Jones and Bartlett, 2003.



"How to Deal with Grief." US Department of Health and Human Services, 2012.



Kübler-Ross, Elisabeth, ed. Death: The Final Stage of Growth. Reprint. New York: Simon & Schuster, 1997.



Kushner, Harold. When Bad Things Happen to Good People. Rev. ed. New York: Schocken Books, 2001.



McBride, Deborah. "Washington's Death with Dignity Program Is a Rarely Used Success, According to New Study." ONS Connect 28, no. 2 (June, 2013): 45.



McFarlane, Rodger, and Philip Bashe. The Complete Bedside Companion: No-Nonsense Advice on Caring for the Seriously Ill. New York: Simon & Schuster, 1998.

What are drug resistance and multidrug resistance (MDR)?




Development of resistance: Drug resistance and MDR are major causes of treatment failure in cancer patients. When exposed to chemotherapeutic drugs, the cancer cell activates processes or synthesizes molecules that can inactivate or eliminate the drugs. Cancer cells have many alternative pathways at their disposal to overcome the toxic effects of chemotherapeutic drugs. Most of these mechanisms have origins in the normal cell. The oncologist recognizes the phenomenon of MDR and has developed treatment programs to delay its onset. Chemotherapy can consist of treatment with single drugs or multiple drugs. Chemotherapy is commonly combined with radiation or surgery. Research is ongoing to develop drugs that specifically target MDR when it develops.




Anticancer drugs have to overcome many challenges before they can accomplish their mission. Tumors are rapidly growing and have a poorly developed vascular system. The cancer cells have difficulty in receiving adequate oxygen and nutrients and therefore adapt to a hypoxic (low-oxygen) environment. This hypoxic environment can cause cancer cells to become resistant to drugs. Drugs have difficulty navigating the poor tumor vascular system to reach the cells. The drugs must be able to pass the cell membrane, navigate the cytoplasm, and reach the nucleus, where most drugs exert their effects. They must accumulate in high concentrations in their active form and must sustain these concentrations long enough to kill the cancer cell.



Drugs against MDR proteins: A major research focus is to develop drugs that counteract MDR proteins. The MDR proteins, known as drug efflux pumps, transport drugs out of cancer cells. These proteins belong to a family of proteins called the adenosine triphosphate (ATP) binding cassette proteins (ABCs). The ABC proteins are overexpressed (increase greatly) when exposed to chemotherapeutic drugs. These proteins reside in the cell membrane and consist of an embedded portion that forms a pore for transport of drugs and an internal portion that binds to the ATP molecule. When the ATP molecule is broken down, energy is released to drive the process.


P-glycoprotein is the main MDR protein that has been studied, and it remains of primary interest. Intensive research has developed first-, second-, and third-generation inhibitors to this protein, with each generation improving on the previous generation. Researchers have begun development of inhibitors that act by binding to the ABC protein and inhibiting its activity. The drugs have diverse chemical structures and origins.


Multidrug resistance-associated protein (MRP1) is also a major target of drug research. Several additional MRP proteins with structural similarities to MRP1 have been identified. Several other MDR proteins have been identified as well, including breast cancer resistant protein, mitoxantrone resistant protein, and others less well characterized.



Cellular changes associated with MDR: MDR is commonly associated with changes in the intracellular distribution of the chemotherapeutic drug. Most cancer therapies target deoxyribonucleic acid (DNA) or nuclear enzymes. When MDR develops, there is a redistribution of drug from the nucleus into cellular vesicles such as the Golgi apparatus, endosomes, and lysosomes. The drugs are then transported toward the plasma membrane and excreted from the cell by the process of exocytosis. This process of elimination is considered passive and is different from the MDR efflux pumps, which require energy input to proceed. The expression of MDR pumps is also associated with altered drug distribution within cancer cells.


Most chemotherapeutic drugs are mildly alkaline and have no charge. MDR cells have a more acidic pH inside subcellular vesicles than that of drug-sensitive cells. When drugs diffuse into the vesicles of MDR cells, they become protonated and take on a charge. The drugs are then trapped in the vesicles and cannot reach the nucleus to exert their effect. They can then be excreted from the cell by the process of exocytosis.


Glutathione and its associated enzyme, glutathionone-S-transferase (GST), are commonly found in the body and serve as a natural detoxification mechanism. GST can increase in the presence of a chemotherapeutic drug in the cancer cell. GST then catalyzes the binding of glutathione to the drug. The drug then becomes more water soluble, less toxic to the cell, and more readily excreted. Research is under way to develop drugs that inhibit GST and thus restore the cancer cell’s sensitivity to the drug.



Drugs that inhibit topoisomerase enzymes: The topoisomerase enzymes control the process of unwinding the DNA double helix during transcription or replication of the DNA molecule. This process is essential during cell division. Because cancer cells are rapidly dividing, topoisomerase inhibitor drugs are attractive treatments against a variety of cancers. To function, the drug must form a three-way complex with DNA and the enzyme. Conditions in the cell that interfere with this formation will lead to resistance. Mutations in the topoisomerase enzymes also cause resistance. Most topoisomerase inhibitors that have been the subject of clinical trials are derivatives of the plant extract camptothecin, although a semisynthetic derivative has also been developed.



Drugs that inhibit DNA synthesis: Rapidly dividing cancer cells have a great need for DNA synthesis, so anticancer drugs such as methotrexate and 5-fluorouracil have been used to block pathways to its synthesis. Methotrexate inhibits the enzyme dihydrofolate reductase, while 5-fluorouracil blocks the enzyme thymidylate synthase. Both of these enzymes are required for the synthesis of nucleotides, the building blocks of DNA. Methotrexate was introduced in the mid-twentieth century for the treatment of acute lymphoblastic anemia, but resistance occurs rapidly. Resistance to the drugs can be due to increased production of the target enzymes, defective transport of the drugs, or increased excretion by efflux pumps.


A number of chloroethyl- and methyl-nitrosourea therapeutic drugs attack the guanine unit of DNA in cancer cells to exert their toxic effect. The cancer cell acquires resistance to the drug by activating the enzyme O6-alkylguanine DNA alkyltransferase (AGT) to repair the damage. O6-benzylguanine inhibits the action of AGT and is used in the clinic in combination with nitrosourea drugs to reverse the resistance. Toxicity problems can occur when these drugs are used at levels needed to attain maximum effectiveness.


Protein kinase C is an enzyme that occupies a key role in the transfer of growth factor signals that result in DNA synthesis and cell division. This enzyme directly affects the expression of several proteins involved in drug resistance. These activities make protein kinase C an attractive target for therapeutic drugs.



Drugs that stimulate apoptosis: Most cancer drugs act by stimulating the process of apoptosis (programmed cell death). The susceptibility of a cancer cell to apoptosis depends on the balance between pro- and antiapoptotic proteins in the cell. When the TP53 protein (the primary proapoptotic protein) discovers genetic damage to the DNA molecule, it summons other proteins to halt cell division, and if necessary, to initiate apoptosis. Most cancers show mutations in the TP53 gene, so that instead of helping to destroy cancer cells, they can even promote cancer. Antiapoptotic proteins, particularly the Bcl-2 family, become more active during chemotherapy, leading to resistance to apoptosis.



Drugs that stimulate ceramide synthesis: Ceramide is the basic unit of sphingomyelin, a lipid structural element of cell membranes. Various stress stimuli, including radiation and chemotherapy, result in the formation of ceramide through the breakdown of sphingomyelin, or through synthesis from other molecules. Ceramide then acts as a second messenger relaying a signal to initiate apoptosis or other biological processes. MDR can result in a reduction in ceramide concentration through conversion to an inactive molecule. This reduces the effectiveness of chemotherapy, since many chemotherapeutic drugs exert their effect through apoptosis. Drugs are under development that increase ceramide levels in tumor cells by promoting ceramide synthesis or by blocking the conversion of ceramide to inactive compounds.



Side effects: Depending on the chemotherapeutic drug administered, a variety of side effects can occur. These can include nausea and vomiting, diarrhea and vomiting, anemia, malnutrition, cognitive effects such as memory loss, depression of the immune system, and toxicity to certain body organs.



Bredel, Markus. “Anticancer Drug Resistance in Primary Human Brain Tumors.” Brain Research Reviews 35 (2001): 161-204.


Ferrarelli, Leslie K. "Overcoming Drug Resistance in Cancer."  Science  347.6217 (2015): 38–39. Print.


Henderson, Brian, and A. Graham Pockley. Cellular Trafficking of Cell Stress Proteins in Health and Disease. Dordrecht: Springer, 2012. Print.


Liscovitch, Mordechai, and Yaakov Lavie. “Cancer Multidrug Resistance: A Review of Recent Drug Discovery Research.” I Drugs 5, no. 4 (April, 2002): 349-355.


Morais, Christudas. Advances in Drug Resistance Research. New York: Nova Science, 2014. Print.


Simon, Sanford M., and Melvin Schindler. “Cell Biological Mechanisms of Multidrug Resistance in Tumors.” Proceedings of the National Academy of Sciences 91 (1994): 3497-3504.


Villanueva, M. Teresa. "Therapeutics: Winning Combination."  Nature Reviews Cancer  15.1 (2015): 2-2. Print.

What are hearing tests?

Indications and Procedures Hearing tests are done to establish the presence, type, and sever...